Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SUTRO BIOPHARMA, INC.

(STRO)
  Report
Delayed Nasdaq  -  04:00 2022-11-28 pm EST
6.980 USD   -5.93%
11/23Sutro Biopharma to Participate in Upcoming Investor Conferences
AQ
11/09Transcript : Sutro Biopharma, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-09-2022 08:35 AM
CI
11/09HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Sector Update: Health Care

06/28/2022 | 03:48pm EST


ę MT Newswires 2022
All news about SUTRO BIOPHARMA, INC.
11/23Sutro Biopharma to Participate in Upcoming Investor Conferences
AQ
11/09Transcript : Sutro Biopharma, Inc. Presents at Credit Suisse 31st Annual Heal..
CI
11/09HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating
MT
11/08Earnings Flash (STRO) SUTRO BIOPHARMA Reports Q3 Revenue $25.1M
MT
11/08SUTRO BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and ..
AQ
11/08Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
CI
11/08Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and S..
AQ
11/03Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology ..
AQ
11/02Sutro Biopharma to Participate in Upcoming Investor Conferences
AQ
10/24Sutro Biopharma, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on SUTRO BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 65,0 M - -
Net income 2022 -127 M - -
Net cash 2022 166 M - -
P/E ratio 2022 -2,72x
Yield 2022 -
Capitalization 401 M 401 M -
EV / Sales 2022 3,62x
EV / Sales 2023 6,41x
Nbr of Employees 259
Free-Float 94,3%
Chart SUTRO BIOPHARMA, INC.
Duration : Period :
Sutro Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUTRO BIOPHARMA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 6,98 $
Average target price 21,38 $
Spread / Average Target 206%
EPS Revisions
Managers and Directors
William J. Newell President, Chief Executive Officer & Director
Edward C. Albini Chief Financial Officer & Secretary
Connie L. Matsui Chairman
Henry Heinsohn Vice President-Technology & Innovation
Trevor Hallam Chief Scientific Officer & President-Research
Sector and Competitors
1st jan.Capi. (M$)
SUTRO BIOPHARMA, INC.-53.09%401
VERTEX PHARMACEUTICALS43.58%80 339
REGENERON PHARMACEUTICALS, INC.16.58%78 631
BIONTECH SE-37.36%37 632
WUXI APPTEC CO., LTD.-35.85%33 214
GENMAB A/S20.53%28 930